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Abstract
Background: Advanced glycation end products (AGEs) are formed during the processing, storage, and cooking of foods. As
part of a western diet, AGEs are consumed in excess and impair glucose metabolism in patients with type 2 diabetes. In the
absence of diabetes, AGE-mediated decreases in insulin sensitivity and signaling have been postulated. However, randomized
studies to test this relationship in humans are limited.
Objective: The primary aim of this trial is to determine whether dietary consumption of AGEs will decrease insulin sensitivity
in healthy overweight adults. A secondary aim is to determine the effects of dietary AGEs on insulin secretion, circulating soluble
receptor for AGEs (sRAGE), and inflammation markers.
Methods: Overweight, but otherwise healthy, non-diabetic adults (N=20) aged 18-50 years old will complete a randomized
cross-over design intervention study alternating low and high (4-fold increase) AGE diets (2-week duration). At baseline,
participants will undergo a medical review including an intravenous glucose tolerance test (IVGTT), a hyperinsulinemic-euglycemic
clamp, and anthropometric measures and questionnaires assessing diet, physical activity, and general wellness. Each test diet will
be followed for 14 days, followed by a 4-week washout period before commencement of the second alternate dietary period.
Energy, macronutrient, and AGE intake will be calculated for each dietary period. Additionally, the AGE content of foods used
in the study will be measured by ultra performance liquid chromatography mass spectrometry. All measurements will be repeated
at the beginning and end of each dietary period. Primary and secondary outcomes will be expressed as a change over the dietary
period for insulin sensitivity, secretion, anthropometric parameters, sRAGE, and inflammation markers and compared by paired
t test and analysis of variance (ANOVA).
Results: The study will be completed in early 2016.
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Conclusion: The proposed trial will provide much needed clinical evidence on the impact of excess dietary AGE consumption
on insulin sensitivity and will indicate whether lowering dietary AGE intake can improve insulin sensitivity and/or secretion,
thereby decreasing risk for type 2 diabetes.
Trial Registration: Clinicaltrials.gov NCT00422253; https://clinicaltrials.gov/ct2/show/NCT00422253 (Archived by Webcite
at http://www.webcitation.org/6ZXLhT89c)
(JMIR Res Protoc 2015;4(3):e93)   doi:10.2196/resprot.4552
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Introduction
In both developed and developing countries, the consumption
of highly processed foods has increased dramatically over the
past 30 years [1]. This change in diet has been associated with
increased exposure to advanced glycation end products (AGEs),
which are formed in foods by processes such as non-enzymatic
browning (Maillard reaction). AGEs and Maillard reaction
products are important for flavor and color and increase the
shelf-life of treated foods [2]. While foods high in sugar and
protein are most susceptible to AGE formation, long-term
storage, heating, and physical or chemical processes may also
produce AGEs even in foods regarded as healthy such as fruit
juice, milk, and cereals. In addition, foods high in fat and sugar
can also facilitate in vivo formation and deposition of AGEs
within tissues [3,4]. Cooking temperature with promotion of
surface browning is also a critical factor: baking, roasting,
frying, and grilling are potent promoters of advanced glycation
[5]. High levels of AGEs are thus found in many common foods
such as heated milk and other dairy foods, baked breads, biscuits
and cookies, toasted breakfast cereals, grilled steak, brewed
beer, and roasted coffee beans.
Type 2 diabetes is a global health problem and in many
developed countries it has already reached epidemic proportions
over the past few decades [6]. There is accumulating evidence
from animal studies indicating that high dietary AGE
consumption contributes to increased insulin levels, insulin
resistance, defects in first phase insulin secretion, and type 2
diabetes [7-9]. Interestingly, low AGE diets can protect against
declining insulin sensitivity and the onset of type 2 diabetes in
animal models, even in the context of high fat intake and marked
weight gain [7,8]. This suggests that it is the high AGE content
in high fat diets and not the fat content per se, as was previously
thought, that impairs glucose metabolism. In addition, successive
generational feeding of a high AGE diet to rodents results in
descendants with increased adiposity, insulin resistance,
impaired insulin signaling, and a proinflammatory phenotype
[10], which further implicates dietary AGEs in the etiology of
type 2 diabetes.
In humans, one clinical trial demonstrated an association
between the low dietary consumption of AGEs and improvement
in insulin sensitivity in patients with type 2 diabetes [11]. Similar
results were seen in another trial in people without diabetes
[12], although macronutrients were not matched in these studies.
Both trials used a homeostasis model assessment (HOMA-IR),
which is an indirect measure of insulin sensitivity. HOMA-IR
is unable to reliably differentiate between the insulin sensitivity
and insulin secretion (HOMA-β) because both are calculated
from fasting glucose and insulin concentrations. No studies
have used gold standard measurements of insulin sensitivity
and secretion to investigate the metabolic effects of high and
low AGE diets. In particular, there is a paucity of data testing
the effects of dietary AGEs on insulin secretion in both animals
and humans. We have recently shown in rodents that changes
in insulin secretion following long-term exposure to AGEs
[13,14] can be prevented with AGE-lowering therapy [13]. In
addition, there is a suggestion that an AGE-RAGE interaction
could mediate β-cell failure from cell [13,15] and animal studies
[16].
To date, there have been no human trials investigating the impact
of a dietary AGE intervention on direct measures of insulin
sensitivity and insulin secretion or on the development of type
2 diabetes. Therefore, our aim is to compare the effects of high
and low AGE diets, followed for 2 weeks, on direct measures
of insulin sensitivity and insulin secretion in healthy yet
overweight or obese individuals without diabetes. We also plan
to assess the contribution of AGE receptors and chronic
low-grade inflammation to the changes in insulin sensitivity
and secretion observed during the trial.
Methods
Study Design and Setting
Overview
This study has a randomized, two period double-blind cross-over
design (Figure 1). We aim for 20 overweight but otherwise
healthy normoglycemic adults, aged 18-50 years to complete
the trial. Participants will commence the study after a 2-week
run-in on their habitual diet, but with restricted intake of alcohol,
fast food, and coffee. Test diets will then each be followed for
2 weeks, separated by a 4-week washout period (return to
habitual diet). Usual levels of physical activity will be continued
throughout the study. Overweight participants will be selected
for enrolment in this study as they represent the average
Australian population, are generally more insulin resistant, more
sedentary, and have higher levels of inflammatory markers, all
factors that increase their risk for type 2 diabetes [17,18].
Participants will be sought using a number of advertising
strategies including posters, flyers, newspaper, and online
advertising and email newsletters from the Alfred Hospital in
Melbourne, Australia.
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Figure 1. Trial protocol.
Inclusion Criteria
Inclusion criteria for the study will include the following (1)
aged 18-50 years, (2) free of diabetes (previously diagnosed or
on the basis of the screening OGTT), (3) generally healthy upon
medical screening, (4) overweight or obese but not morbidly
obese (body mass index (BMI)>25 kg/m2 but <40 kg/m2), and
(5) stable body weight, having exhibited a weight change <5
kg in the preceding year with no intention to lose weight or
change physical activity during the trial.
Exclusion Criteria
Exclusion criteria will include (1) substance abuse including
smoking and high alcohol use (>4 and >2 standard drinks per
week for males and females, respectively), (2) known allergies,
(3) use of medications including vitamin supplements and
hormonal contraceptives, (4) any renal, cardiovascular,
hematological, respiratory, gastrointestinal, endocrine or central
nervous system diseases, psychiatric disorders, active cancer
within the preceding 5 years, or the presence of acute
inflammation or infection based on the medical history and the
physical and laboratory examinations obtained at recruitment,
and (5) women in menopause, or pregnant and/or lactating.
Statistical Considerations
Sample Size Calculation
The sample size is estimated on the basis of the primary
hypothesis including being able to detect a 20% difference in
insulin sensitivity following dietary AGE modification using
G*Power, an online tool to compute statistical power analyses.
This effect size is clinically significant and similar to that seen
after a 6-month intervention period using troglitazone, an insulin
sensitizing therapy. Troglitazone improved insulin sensitivity
as measured by glucose clamp in obese, non-diabetic individuals
[19] whose initial glucose disposal rate was 8.1 (+2.0)
mg/kg/min. To detect a 20% difference in insulin sensitivity in
a cross-over design by paired t test, we will require complete
data from 20 individuals (power 80%, alpha 5%, SD 1.0).
Data Analysis
Descriptive analysis will be performed on baseline
characteristics and covariates. We will use paired t test to
determine the significance of the change in measured parameters
during test diets. Multiple regression will be used to assess the
determinants of insulin secretion after adjusting for covariates.
Dietary order will be included in multiple regression models as
a between participant variable. Carryover effects will be tested
in an expanded model including diet and period interaction
when evaluating the effects of diet over the 2 test periods. Period
effects refer to a change between intervention and measurement
periods and within subjects, which would have occurred
independently from any diet given. Plausible period effects in
diet-based trials might arise from behavioral changes by
participants as a result of enrolment in a dietary-based trial
Adjustment to P values for multiple comparisons will be
performed using the Holm method, and statistical significance
will be assumed when P<.05.
Screening
The study timelines are presented in Figure 1. Female
participants will be required to commence metabolic testing
while they are in the follicular phase of their menstrual cycle
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and a urine pregnancy test will be performed to exclude
pregnancy. At visit 1, screening will be undertaken by a
registered medical practitioner who will collect the medical
history and perform a physical examination including
measurement of blood pressure, height, body weight, and waist
and hip circumference using the methods outlined in the
following sections.
At the second visit, participants will undergo an OGTT with
measurement of fasting and 2-hour glucose levels to exclude
diabetes according to the World Health Organization (WHO)
1999 criteria [20]. Blood samples will be analyzed by a single
accredited laboratory for full blood count, kidney and liver
function, lipid profile, and C-reactive protein (CRP) as a marker
of inflammation. Participants will also be given a 3-day food
diary to record their habitual dietary intake and this will be
returned on their next visit where it will be used to aid the
dietitian in the development of individualized test diets (as
following).
Baseline Assessment
Baseline assessments will commence at the third visit which
will involve measurement of blood pressure and body
composition by bioimpedance. At the fourth and fifth baseline
visits, an intravenous glucose tolerance test (IVGTT) and a
hyperinsulinemic euglycemic clamp will be performed (detailed
below in Data Collection and Analyses). Participants will
complete the International Physical Activity Questionnaire
(IPAQ) questionnaire to assess habitual physical activity [21].
Randomization and Blinding
Following successful screening and baseline assessment,
subjects will be randomized by a computer program to
commence the study with either the high or low AGE diet.
Randomization will be done in blocks of four by gender using
a relevant computer program to ensure balance in each test
group and will be conducted by a researcher from within our
department who is not involved in the trial data collection,
analysis, or reporting. Diet type will be coded as (red or blue)
by the dietitian, so that participants and blinded investigators
remain unaware of which dietary period they are undertaking
or how diet might affect glucose metabolism. Clinical and
laboratory investigators will also be masked to diet allocation.
Intervention
Using Australian food composition data in addition to data on
the AGE, N-carboxymethyllysine (CML), N-carboxyethyllysine
(CEL), and methylglyoxal-derived hydroimidazolone (MGH1)
content of common foods [3], a set of carefully matched
alternative food choices has been designed with each alternate
food choice having similar macronutrient and total energy
content but differing greatly in AGE (referred to as the "Food
List") [9].
To ascertain dietary AGE content, food items used in the study
were obtained from local supermarkets and prepared according
to the instructions of the study. To prevent neo-formation of
CML during acid hydrolysis, a reduction step with sodium
borohydride was used. Food items containing <20% fat were
mixed and subsequently deproteinized with 1000 µl cold (4°C)
TFA. Food items >20% fat were mixed and subsequently
deproteinized with a mixture of chloroform:methanol (2:1, v/v)
[22]. After centrifugation (4300 g, 4°C, 20 min), the supernatant
(TFA) or lower phase (chloroform) was carefully removed. For
validation experiments, 25 µL of a standard solution (six point
calibration curve; 5250-0 nmol/L CML, 6250-0 nmol/L CEL
and 14749-0 nmol/L MGH1) was added. Samples were then
hydrolyzed by adding 500 µl 6N HCl and incubated for 16 hours
at 100°C. After hydrolysis, 40 µL hydrolysate and 20 µL internal
standard (containing 1432 nmol/L 2H2-CML, 1378 nmol/L
2H4-CEL, and 1322 nmol/L 2H3-MGH1) were mixed in a
reaction vial. The mixture was evaporated to dryness under a
stream of nitrogen gas at 70°C. To increase sensitivity during
electrospray ionization and increase retention time using
reversed phase chromatography, samples were subsequently
derivatized with 100 µL 1-butanol:HCl (3:1, v/v) for 90 minutes
at 70°C. After derivatisation, the samples were evaporated to
dryness under nitrogen, redissolved in 300 µL water, mixed,
and subsequently centrifuged at 20,000 g for 20 minutes.
AGE-free adducts in foods were measured.
Using the 3-day diet diary recorded by each participant during
the "run-in" period, the dietitian will help participants select
foods for their first test diet from the "Food List", guided by
their individual preferences and energy requirements. The
content of their second test diet will comprise the alternate
paired foods. Food choices on the high-AGE diet thus will
approximate a typical Australian diet, while the isoenergetic
low AGE diet, matched for macronutrient content, will have
reduced AGE content through altered cooking techniques [23]
and use of differently processed foods. All food required for
both test diets will be provided weekly to the participants as
ready-to-eat items or as packed food portions together with
detailed instructions for storage and re-heating or cooking
(method, temperature, duration). Participants will be asked to
eat to appetite throughout both dietary periods to maintain
constant body weight and to complete a daily record indicating
the number of portions eaten for each food item supplied, any
foods not consumed, or any additional foods that were eaten.
Participants will be contacted twice a week by the dietitian who
designed the dietary protocol to resolve any problems and to
ensure dietary compliance.
Follow-Up Visits
Participants will be scheduled for their follow-up visits after
completing each test diet for 2 weeks. All the procedures
performed during baseline assessment including blood pressure,
anthropometry, IVGTT, physical activity questionnaire, and
glucose clamp will be repeated with the exception of the OGTT,
as this will only be performed once at screening to identify
undiagnosed diabetes.
Safety Considerations
During the screening, baseline, and follow-up procedures, any
medical conditions or abnormalities detected will be promptly
discussed with the participant by a qualified medical practitioner
involved in the study. Where applicable, participants will be
treated, referred, and/or advised to visit their general practitioner
for follow-up. All participants will be advised of the results of
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their medical review and blood tests after completion of the
study, and a medical practitioner from the study team will
provide them with strategies to improve their diabetes and
cardiovascular risk profile.
Ethics
This trial has received ethical approval from the Alfred Hospital
Ethics Committee in Melbourne, Australia (Protocol ID: 36/06).
Outcome Measurements
The primary outcome in this trial is the difference (change) in
insulin sensitivity between the 2 diets. Secondary outcomes
include changes in insulin secretion, body weight, body mass
index (BMI), waist, waist-to-hip ratio (WHR), resting systolic
and diastolic blood pressure, lipid profile and markers of
inflammation (ie, interleukin (IL)-1ß, IL-6, IL-8, and IL-10),
tumour necrosis factor-α (TNFα), macrophage migration
inhibitory factor (MIF), monocyte chemotactic protein-1
(MCP-1), C-reactive protein (CRP), nuclear factor-κB (NF-κB)
activity, and circulating sRAGEs.
Data Collection and Analyses
Anthropometry
Body Mass Index (BMI) and Percent Body Fat
Body weight (kg) and height (cm) will be measured using a
digital scale (BC-418MA, Tanita UK Ltd) and stable stadiometer
(Seca 206), respectively, at baseline and following the
intervention period during which participants will be lightly
clothed and without shoes. BMI will be calculated as weight
(kg)/height (m)2. Body composition will be determined by
bioelectrical impedance analysis (BC-418MA, Tanita UK Ltd).
Waist-To-Hip Ratio (WHR)
Central adiposity will be assessed using waist and hip
circumferences, taken in duplicate by an experienced researcher
using a constant-tension tape. Waist circumference will be
measured at the midpoint between the upper iliac crest and the
lowermost rib at the end of a normal expiration, while hip
circumference will be taken around the widest part of the
buttocks. The WHR will be determined as waist (cm)/hip (cm).
Metabolic Measures
All metabolic testing will be performed after a 12-hour overnight
fast. Prior to metabolic testing, participants will be asked to
abstain from strenuous exercise and caffeine for 3 days. The
first metabolic testing day in females will be scheduled in the
follicular phase of their menstrual cycle.
Oral Glucose Tolerance Test (OGTT)
Participants will ingest 75 g of glucose over 2 minutes. Blood
samples will be drawn at 0 and 120 minutes to analyze plasma
glucose levels and to determine diabetes status (WHO 1999
criteria).
Intravenous Glucose Tolerance Test (IVGTT)
Using IVGTT, acute insulin secretory response will be
measured. First, baseline blood will be collected at -10 and 0
minutes, after which 50 ml of 50% glucose will be delivered
intravenously over a 3-minute period. Blood will then be
collected for measurement of insulin at the 3, 4, 5, 6, 8, 10, 15,
20, 25, and 30 minute time points. The early insulin secretory
response will be calculated as the mean incremental plasma
insulin level from the 3rd to the 5th minute after the glucose
bolus.
Hyperinsulinemic Euglycemic Clamp
A euglycemic glucose clamp will be used to measure insulin
sensitivity. After collecting baseline blood and plasma glucose
levels at 0 minutes, the clamp will be initiated by an intravenous
bolus injection of insulin (9 mU/kg). Insulin will then be
constantly infused at a rate of 40 mU/m2/min for approximately
120 minute into an arm vein, whilst glucose is variably infused
to maintain euglycemia. Plasma glucose values will be
monitored every 5 minutes during the clamp while the variable
infusion rate of glucose is adjusted to maintain blood glucose
at a constant concentration of 5 mmol/L for the last 40 minutes
of the clamp.
Plasma glucose concentrations will be measured by the glucose
oxidase method (ELM 105 Radiometer). Plasma insulin levels
will be measured by chemiluminescent microparticle
immunoassay and plasma high sensitivity CRP will be
determined by immunotubimetric assay (Abbott Archicentre
ci162000).
Measurement of Advanced Glycation End Products
(AGEs) and Their Receptors
The concentrations of AGE- (CML, CEL, and MG-H1) modified
proteins in serum and free AGEs in urine will be quantified
using UPLC MSMS as previously described [24].
AGE-modified proteins will also assayed [25] in urine (neat)
using an indirect ELISA as previously described [26].
The pool of sRAGE (circulating RAGE from proteolytic
cleavage and AGER gene transcription; RnD Systems) and
endogenous secretory RAGE (esRAGE) (circulating RAGE
from AGER1 gene transcription only) will be analyzed in plasma
by ELISA according to the manufacturer’s instructions.
Cardiovascular Measures
Blood Pressure
Resting systolic and diastolic blood pressure and pulse rate will
be measured using an automated oscillometric measurement
system (Omron) after a 30 minute rest. The mean blood pressure
derived from 3 measurements will be recorded.
Lipid Profile
Lipid profile-related parameters to be measured include plasma
total cholesterol, triglycerides, and low density lipoprotein
(LDL) and high density lipoprotein (HDL) cholesterol using a
standard commercial enzymatic assay (Beckman Coulter
LX20PRO Analyzer and Synchron) and Systems Lipid and
Multi Calibrators (Beckman Coulter Diagnostics).
Inflammatory Markers
Cytokines and Chemokines
Plasma inflammatory markers (IL-1ß, -6, -8 and -10, TNFα,
MIF, and MCP-1) will be measured using a commercial
automated chemiluminescent enzyme immuno assay (EIA) and
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immulite analyzer (Diagnostic Products Corporation), while
plasma CRP will be analyzed using highly sensitive near infrared
particle immunoassay rate methodology and a Beckman Coulter
Synchron LX system Chemistry Analyzer (Beckman Coulter
Inc).
Nuclear Factor-κB (NF-κB) Activity
Nuclear extracts of white blood cells will be obtained and
analyzed for the binding capacity of the p50/p65 subunit of
NF-κB to an NF-κB oligonucleotide consensus sequence as per
the manufacturer’s instructions (Active Motif, CA, USA).
Self-Reported Measures
Nutrient Analyses
During the test diets, the daily records of all foods eaten will
be collected weekly from study participants. Food intake will
then be analyzed for nutrient content by a dietitian using an
Australian Food Composition program. Based on these records,
the dietary intake of CML, CEL, and MGH1 will be determined
for each participant over each dietary period. The mean daily
energy, macronutrient, and AGE intake of participants during
the 2 test diets will then be compared.
International Physical Activity Questionnaire (IPAQ)
The validated IPAQ determines the type of everyday physical
activity that people engage in [21]. We will use the short version
of IPAQ as a timely, convenient method to determine whether
study participants have made any change in their physical
activity which could influence our study outcomes. The short
IPAQ asks participants to reflect on the past 7 days and report
time spent on vigorous activity (eg, aerobics), moderate activity
(eg, carrying light loads), walking, and sitting [21].
Discussion
Principal Findings
To the best of our knowledge, there is no human clinical trial
published investigating the effect of high and low AGE diets
on insulin sensitivity and secretion in individuals without
diabetes, employing gold standard measures of insulin sensitivity
and secretion, and comprehensively investigating mechanisms
including chronic low-grade inflammation.
Insulin resistance increases with obesity and is a key pathogenic
process underpinning type 2 diabetes. Interventions that reduce
insulin resistance such as lifestyle measures including diet and
exercise resulting in weight loss, as well as pharmacological
therapies are used to prevent and treat type 2 diabetes [27].
However, to date, these agents have failed to decrease the burden
of this disease. Diabetes is a major cause of morbidity and
mortality, primarily due to chronic complications including an
increased risk of cardiovascular disease. It is vital that additional
effective primary prevention strategies are established to reduce
insulin resistance and prevent and manage type 2 diabetes [28].
The current trial should thus inform and advance this important
field of research.
By demonstrating that intake of a low AGE diet improves insulin
sensitivity and/or secretion, large scale interventions using low
AGE diets could potentially become a mainstream strategy for
diabetes prevention in overweight and obese individuals. This
strategy would offer a cost-effective and easily administered
intervention that could have a considerable impact on health
outcomes in Australia and worldwide since it can be achieved
by simple changes in cooking methods by individuals and/or
processing by the food industry. Such improvements will not
only lower diabetes risk, but since AGEs are also known to play
an essential role in the development of micro-vascular
complications, a low AGE dietary intervention could reduce
cardiovascular risk factors as well as chronic low grade
inflammation [11]. Therefore, lowering AGEs could have
beneficial effects on decreasing risk factors associated with a
wide range of metabolic conditions. High-quality clinical trials
such as this are, therefore, an important first step towards
elucidating the effects of a low AGE diet in promoting health
and well-being by improving insulin sensitivity, decreasing
cardiovascular risk factors, and potentially decreasing the risk
of type 2 diabetes and its associated micro and macro vascular
co-morbidities.
There is a paucity of human data investigating the effect of
AGEs on insulin resistance in humans. One previous study by
Uribarri et al [11] examined the effect of dietary AGE restriction
on glucose homeostasis in 18 diabetic and 18 healthy
individuals. They showed that in patients with type 2 diabetes,
but not in healthy individuals, insulin resistance (estimated by
HOMA-IR) improved after 4 months of dietary AGE restriction.
We have recently published another trial in overweight and
obese people without diabetes that demonstrated an
improvement of HOMA-IR with a low AGE dietary intervention
when compared to a high AGE diet [12]. In both of these studies,
the intake during the 2 diets was isocaloric but not macronutrient
matched. Therefore, some of the changes observed could have
been due to differences in macronutrient intake. In addition,
these studies depended on HOMA-IR, which is calculated from
fasting glucose and insulin levels and hence cannot differentiate
between insulin sensitivity and secretion. No human trials with
AGE dietary manipulation have been carried out to date
measuring insulin secretion, but we and others have previously
shown that a greater exposure to AGEs either at very high
concentrations or for an extended duration may ultimately impair
pancreatic beta cell function resulting in reduced insulin
secretion, particularly of the first phase in cells and in animal
models [13,15]. Such effects appear to be mediated by changes
in the AGE receptor RAGE [13,14,16]. A few previous studies
have suggested that cooking methods, which result in lower
AGEs in the food, can alter glucose homeostasis, but these
studies used either single meal challenges [29-31] or did not
account for changes in body weight [32].
With regard to putative mechanisms involved, AGE modulation
could impact on insulin sensitivity via effects on insulin
signaling pathways [33,34], likely mediated by a chronic
low-grade inflammation [35]. Consistent with this, in the study
by Uribarri [11], a diet low in AGE content was associated with
a decrease in circulating concentrations of inflammatory
cytokines in patients with type 2 diabetes but not healthy
individuals.
Recent reports have also demonstrated a possible role of another
AGE receptor AGE-R1 in the development of insulin resistance
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in the type 2 diabetic population [11]. In the study by Uribarri,
a diet low in AGE content was associated with an elevation in
AGE-R1 expression on peripheral blood mononuclear cells
(PBMC)s in patients with type 2 diabetes but not healthy
individuals [11].
Methodological Considerations
The strengths of the proposed study protocol include the gold
standard study design, randomization, and double-blinding of
both participants and investigators to limit bias. Other major
strengths include the cross-over design which controls for
individual variation between participants, the assessment of
confounders such as dietary macronutrient and energy content
and physical activity, and the use of direct rather than indirect
measures of insulin sensitivity and secretion such as the OGTT,
IVGTT, and the gold standard euglycemic clamp. Determination
of many blood components will also allow for the
comprehensive exploration of potential mechanisms involved.
We will also have a comprehensive analysis of the dietary AGEs
which are consumed during the study period which will be
matched with AGE levels in both the blood and urine.
Despite these strengths, there are also potential limitations. First,
self-selection bias may be present given that recruitment is based
on voluntary participation by interested subjects. These subjects
may not represent the entire target population because they may
be characteristically different to other volunteers (ie, potentially
more health conscious). Secondly, we are only recruiting
overweight or obese adults (BMI>25), who are otherwise healthy
(not medicated and without diabetes etc), and therefore the
results of the study will not be generalizable to other populations
such as those within a healthy weight range or those with
diagnosed diabetes or other medical conditions and
co-morbidities. Third, our study will only measure risk factors
such as blood pressure, fasting glucose, and insulin sensitivity
and insulin secretion. Longitudinal follow-up studies would be
necessary to ascertain if change in these risk factors translates
into decreased incidence of type 2 diabetes.
Conclusions
Type 2 diabetes and its associated complications are associated
with significant morbidity and mortality as well as healthcare
costs. Insulin resistance, the key risk factor for type 2 diabetes,
increases with increasing body weight. While existing research
suggests that consumption of a low AGE diet may prevent
insulin resistance and type 2 diabetes, well-designed randomized
trials are lacking. If our clinical trial shows that low AGE diet
can improve risk for diabetes, our study may have important
public health implications and could lead to feasible and
cost-effective strategies to prevent type 2 diabetes and its
complications.
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AGE: advanced glycation end product
BMI: body mass index
BP: blood pressure
CEL: carboxyethyllysine
CML: carboxymethyllysine
CRP: C-reactive protein
CVD: cardiovascular disease
DXA: dual-energy x-ray absorptiometry scan
ELISA: enzyme-linked immunosorbent assay
HbA1c: hemoglobin A1C
HDL/ LDL: high-/low-density lipoprotein cholesterol
HOMA-IR: homeostasis model assessment for insulin resistance
IL: interleukin
INFγ: interferon-gamma
IPAQ: International Physical Activity Questionnaire
IU: international units
IVGTT: intravenous glucose tolerance test
MCP-1: monocyte chemotactic protein 1
MGH1: methylglyoxal-derived hydroimidizolone
MIF: macrophage migration inhibitory factor
NF-κB: nuclear factor-κB
NHMRC: National Health and Medical Research Council
OGTT: oral glucose tolerance test
sRAGE: soluble receptor for advanced glycation end products
TG: triglycerides
TNFα: tumour necrose factor-α
WHR: waist-to-hip ratio
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